The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
Igor Puzanov
Consultant or Advisory Role - Amgen
Mohammed M. Milhem
No relevant relationships to disclose
Robert Hans Ingemar Andtbacka
Consultant or Advisory Role - Amgen
David R. Minor
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Omid Hamid
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Ai Li
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Michael Chastain
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Kevin Gorski
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Abraham Anderson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ari M. Vanderwalde
Employment or Leadership Position - Amgen
Jeffrey Chou
Employment or Leadership Position - Amgen
Howard Kaufman
Consultant or Advisory Role - Amgen